Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Emergence of new ALK mutations at relapse of neuroblastomaGudrun Schleiermacher, Niloufar Javanmardi, Virginie Bernard, et al.
The EMBO Journal|November 11, 2024
METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastomaKetan Thombare, Roshan Vaid, Perla Pucci, et al.
Cancer Research Communications|August 23, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA AnalysisTorben Ek, Raghda R Ibrahim, Hartmut Vogt, et al.
Molecular Cancer|August 31, 2024
Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastomaThale K Olsen, Jörg Otte, Shenglin Mei, et al.
Drug Delivery|May 2, 2026
Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic reviewAmirhossein Masroor, Nienke Streefkerk, Martine Van Grotel, et al.
Cancer Cell|March 14, 2018
Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory AxisTanmoy Mondal, Prasanna Kumar Juvvuna, Agnete Kirkeby, et al.
Cancer Letters|May 4, 2025
Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progressionJelena Milosevic, Susanne Fransson, Johanna Svensson, et al.
Nature Genetics|April 9, 2021
Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma originPolina Kameneva, Artem V Artemov, Maria Eleni Kastriti, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
Expert Opinion on Drug Discovery|June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma projectLucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Pageof 17